Cargando…

ID4: a new player in the cancer arena

Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Dell'Orso, Stefania, Ganci, Federica, Strano, Sabrina, Blandino, Giovanni, Fontemaggi, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053547/
https://www.ncbi.nlm.nih.gov/pubmed/21293053
_version_ 1782320389930614784
author Dell'Orso, Stefania
Ganci, Federica
Strano, Sabrina
Blandino, Giovanni
Fontemaggi, Giulia
author_facet Dell'Orso, Stefania
Ganci, Federica
Strano, Sabrina
Blandino, Giovanni
Fontemaggi, Giulia
author_sort Dell'Orso, Stefania
collection PubMed
description Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Several evidences indicate that Id proteins are associated with loss of differentiation, unrestricted proliferation and neoangiogenesis in diverse human cancers. Recently, we identified Id4 as a transcriptional target of the protein complex mutant p53/E2F1/p300 in breast cancer. Id4 protein binds, stabilizes and enhances the translation of mRNAs encoding proangiogenic cytokines, such as IL8 and GRO-alpha, increasing the angiogenic potential of cancer cells. We present here an overview of the current experimental data that links Id4 to cancer. We provide evidence also of the induction of Id4 following anticancer treatments in mutant p53-carrying cells. Indeed, mutant p53 is recruited to a specific region of the Id4 promoter upon DNA damage. Our findings indicate that Id4, besides its proangiogenic role, might also participate in the chemoresistance associated to mutant p53 proteins exerting gain of function activities.
format Online
Article
Text
id pubmed-4053547
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-40535472014-06-17 ID4: a new player in the cancer arena Dell'Orso, Stefania Ganci, Federica Strano, Sabrina Blandino, Giovanni Fontemaggi, Giulia Oncotarget Research Perspective Id proteins (Id-1 to 4) are dominant negative regulators of basic helix-loop-helix transcription factors. They play a key role during development, preventing cell differentiation while inducing cell proliferation. They are poorly expressed in adult life but can be reactivated in tumorigenesis. Several evidences indicate that Id proteins are associated with loss of differentiation, unrestricted proliferation and neoangiogenesis in diverse human cancers. Recently, we identified Id4 as a transcriptional target of the protein complex mutant p53/E2F1/p300 in breast cancer. Id4 protein binds, stabilizes and enhances the translation of mRNAs encoding proangiogenic cytokines, such as IL8 and GRO-alpha, increasing the angiogenic potential of cancer cells. We present here an overview of the current experimental data that links Id4 to cancer. We provide evidence also of the induction of Id4 following anticancer treatments in mutant p53-carrying cells. Indeed, mutant p53 is recruited to a specific region of the Id4 promoter upon DNA damage. Our findings indicate that Id4, besides its proangiogenic role, might also participate in the chemoresistance associated to mutant p53 proteins exerting gain of function activities. Impact Journals LLC 2010-05-01 /pmc/articles/PMC4053547/ /pubmed/21293053 Text en Copyright: © 2010 Dell'Orso et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Dell'Orso, Stefania
Ganci, Federica
Strano, Sabrina
Blandino, Giovanni
Fontemaggi, Giulia
ID4: a new player in the cancer arena
title ID4: a new player in the cancer arena
title_full ID4: a new player in the cancer arena
title_fullStr ID4: a new player in the cancer arena
title_full_unstemmed ID4: a new player in the cancer arena
title_short ID4: a new player in the cancer arena
title_sort id4: a new player in the cancer arena
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053547/
https://www.ncbi.nlm.nih.gov/pubmed/21293053
work_keys_str_mv AT dellorsostefania id4anewplayerinthecancerarena
AT gancifederica id4anewplayerinthecancerarena
AT stranosabrina id4anewplayerinthecancerarena
AT blandinogiovanni id4anewplayerinthecancerarena
AT fontemaggigiulia id4anewplayerinthecancerarena